Vancouver, BC-based NervGen Pharma Corp . (TSX-V: NGEN) (OTCQX: NGENF), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis, to generate new treatments for Alzheimer's disease (AD).

"NervGen's platform technology provides an innovative approach to Alzheimer's disease and has received positive affirmation from several Alzheimer's disease opinion leaders," said Bill Radvak, NervGen's Executive Chairman. "The essence of our technology is that it unlocks a damaged nervous system's natural ability to repair itself which could translate to helping people suffering from Alzheimer's disease."